Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Mutation of the tumor suppressor gene, TP53, is associated with abysmal survival outcomes
in acute myeloid leukemia (AML). Although it is the most commonly mutated gene in cancer …

PURPOSE Outcomes are poor in TP53-mutant (m TP53) acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant …

Abstract The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and
management of acute myeloid leukemia (AML) have become fundamental guidelines to …

Simple Summary TP53 mutations are seen in 5–10% of de novo MDS and AML, but 25–
40% of therapy-related MDS and AML. Despite the addition of recent drugs to the common …

The aim of our review has been to give an appropriate idea of analogies and differences
between primitive MDS (p-MDS) and t-MDS throughout an accurate reviewing of English …

We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic
hematopoietic stem cell transplantation (HSCT) in TP53-mutated acute myeloid leukemia …

The treatment of acute myeloid leukemia (AML) with adverse genetics remains
unsatisfactory, with very low response rates to standard chemotherapy and shorter durations …

Over the past decade, our understanding of AML pathogenesis and pathophysiology has
improved significantly with mutational profiling. This has led to translational advances in …

In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS)
have been proposed: the International Consensus Classification (ICC) and the 2022 World …